Drugs / Atezolumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04267237 | Mar 2021 → Sep 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atezolumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04267237 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT04267237 ↗ |